logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
CGON
CG Oncology, Inc.
75.16
2 x 53.62
2 x 92.80
bid
ask
+
0.82
1.10%
2 @ 07:50 PM
76.05 +0.89 (1.18%)
Ytd81.02%
1y180.24%
72.12
day range
76.14
26.25
52 week range
80.97
Open74.09Prev Close74.34Low72.12High76.14Mkt Cap6.66B
Vol840.74KAvg Vol979.82KEPS-2.69P/EN/AForward P/E-24.88
Beta0.23Short Ratio12.96Inst. Own113.61%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0950-d Avg72.86200-d Avg60.221yr Est91.08

CGON News

10 Health Care Stocks Whale Activity In Today’s Session
benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
prnewswire.com
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

CG Oncology: Circling Back After Huge Rally
seekingalpha.com
CG Oncology: Circling Back After Huge Rally

CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy a

CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System
defenseworld.net
CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON)

benzinga.com
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and low
benzinga.com
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85

Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and ra
benzinga.com
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85

Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus
benzinga.com
CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst co

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported fin

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
globenewswire.com
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
globenewswire.com
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet O

Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorab
benzinga.com
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Moti

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. R

CG Oncology Stock Gains 12% in Three Months: What's Driving It?
zacks.com
CG Oncology Stock Gains 12% in Three Months: What's Driving It?

CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It m

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
marketbeat.com
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
marketbeat.com
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-

CG Oncology to Present at Upcoming Investor Conferences in June
globenewswire.com
CG Oncology to Present at Upcoming Investor Conferences in June

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthu

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
marketbeat.com
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology NASDAQ: CGON executives used an RBC Capital Markets fireside chat to outline recent clin

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
globenewswire.com
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder C

Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the d
benzinga.com
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a B
benzinga.com
CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 Trial

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the IT

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
globenewswire.com
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intraves

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the IT

CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
marketbeat.com
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears

CG Oncology NASDAQ: CGON executives said the company remains on track to complete a rolling biologic
benzinga.com
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82

Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raise

CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript

CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
globenewswire.com
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Stron

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in

benzinga.com
JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96

JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises th

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
benzinga.com
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
benzinga.com
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

CG Oncology (NASDAQ:CGON) reported mixed results for Q1, with losses of 71 cents per share and sales
benzinga.com
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and rai
benzinga.com
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $77

Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raise
benzinga.com
Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $80

Wedbush analyst Yun Zhong maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the pr

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.71 per share versus the Zacks Consensu
benzinga.com
CG Oncology Q1 EPS $(0.71) Misses $(0.57) Estimate, Sales $1.083M Beat $493.182K Estimate

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.71) per share which missed the analyst co
benzinga.com
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $79

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and rai
benzinga.com
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $100

HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Bu

What Analysts Are Saying About CG Oncology Stock
benzinga.com
What Analysts Are Saying About CG Oncology Stock
benzinga.com
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $80

HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Bu

CG Oncology Q4 Earnings Report: What Investors Need to Know
benzinga.com
CG Oncology Q4 Earnings Report: What Investors Need to Know
benzinga.com
CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate

CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.51) per share which beat the analyst cons

Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts
benzinga.com
Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts
benzinga.com
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $75

Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises

What Analysts Are Saying About CG Oncology Stock
benzinga.com
What Analysts Are Saying About CG Oncology Stock
benzinga.com
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $73

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and rai
benzinga.com
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $70

Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and ra
benzinga.com
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $66

Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
benzinga.com
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday
benzinga.com
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday